ExploreWatchlistsPricing
  1. JP-listed companies
  2. Delta-Fly Pharma, Inc.
  3. Financials
  4. Return on equity (%)

Delta-Fly Pharma, Inc. (4598)

Market cap
¥2.1B
P/E ratio
-1.2x
Delta-Fly Pharma develops cancer treatments using a unique "modular drug discovery" approach that builds new drugs from existing cancer-fighting compounds.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndReturn on equity (%) (Million JPY)YoY (%)
Mar 31, 2025-227.9+61.35%
Mar 31, 2024-141.2+7.59%
Mar 31, 2023-131.3+124.76%
Mar 31, 2022-58.4+40.00%
Mar 31, 2021-41.7-25.45%
Mar 31, 2020-56+79.70%
Mar 31, 2019-31.1+0.61%
Mar 31, 2018-30.9

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat